These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1404 related articles for article (PubMed ID: 24569463)

  • 21. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
    Li B; Huang L; Ruan J
    Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
    Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
    Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Antimicrobial Peptide Merecidin Inhibit the Metastasis of Triple-Negative Breast Cancer by Obstructing EMT via miR-30d-5p/Vimentin.
    Ma F; Song J; He M; Wang X
    Technol Cancer Res Treat; 2024; 23():15330338241281310. PubMed ID: 39267432
    [No Abstract]   [Full Text] [Related]  

  • 28. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
    Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
    Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.
    Terashima M; Sakai K; Togashi Y; Hayashi H; De Velasco MA; Tsurutani J; Nishio K
    Springerplus; 2014; 3():417. PubMed ID: 25140293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
    Kashyap A; Umar SM; Dev J R A; Prasad CP
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
    Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis.
    Qi HW; Xin LY; Xu X; Ji XX; Fan LH
    J Transl Med; 2014 Jan; 12():22. PubMed ID: 24456611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sanguinarine impedes metastasis and causes inversion of epithelial to mesenchymal transition in breast cancer.
    Ghauri MA; Su Q; Ullah A; Wang J; Sarwar A; Wu Q; Zhang D; Zhang Y
    Phytomedicine; 2021 Apr; 84():153500. PubMed ID: 33626427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K; Xu C; Wu J; Du B; Liu Q; Sui Y; Song C; Zhang J; Tang H; Chen J
    Sci China Life Sci; 2024 Sep; 67(9):1849-1866. PubMed ID: 38900236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
    Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
    PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.